Updated ADAURA Data Reinforce Adjuvant Osimertinib as SOC for EGFR-Mutated, Stage IB-IIIA NSCLC
September 11th 2022
Adjuvant osimertinib resulted in a 77% reduction in the risk of disease recurrence or death in patients with EGFR-mutated, stage II to IIIA non–small cell lung cancer, with a disease-free survival improvement observed irrespective of prior adjuvant chemotherapy or disease stage.